Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models

Kyong Hwa Jun, Jung Eun Lee, Se Hoon Kim, Ji Han Jung, Hyun Joo Choi, Young Il Kim, Hyung Min Chin, Seung Ho Yang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Gastric cancer is the second most common cause of cancer-related death worldwide. Although brain metastasis is a rare complication of gastric cancer, no standard therapy for gastric cancer brain metastasis has been established. We attempted to identify biological markers that predict brain metastasis, and investigated how to modulate such markers. A case-control study of patients newly diagnosed with gastric cancer who had developed brain metastasis during follow-up, was conducted. These patients were compared with patients who had advanced gastric cancer but no evidence of brain metastasis. Immunohistochemistry was used to analyze the expression of E-cadherin, N-cadherin, MSS1, claudin-3, claudin-4, Glut1, clusterin, ITGB4, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) and p53. The expression of VEGF tended to be higher in the case group (33.3 vs. 0%, p=0.055). Median survival was significantly correlated with vascular invasion (12 vs. 33 months, p=0.008) and N-cadherin expression (36 vs. 12 months, p=0.027). We also investigated the effects of metformin in tumor-bearing mouse models. VEGF expression was decreased and E-cadherin increased in the metformin-treated group when compared with the control group. The expression of the mesenchymal marker MMP9 was decreased in the metformin-treated group. Brain metastasis of advanced gastric cancer was associated with the expression of VEGF. Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition.

Original languageEnglish
Pages (from-to)2047-2053
Number of pages7
JournalOncology Reports
Volume34
Issue number4
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Metformin
Cadherins
Brain Neoplasms
Vascular Endothelial Growth Factor A
Stomach Neoplasms
Neoplasm Metastasis
Brain
Claudin-3
Claudin-4
Clusterin
Epithelial-Mesenchymal Transition
Epidermal Growth Factor Receptor
Blood Vessels
Case-Control Studies
Neoplasms
Biomarkers
Immunohistochemistry
Control Groups
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jun, Kyong Hwa ; Lee, Jung Eun ; Kim, Se Hoon ; Jung, Ji Han ; Choi, Hyun Joo ; Kim, Young Il ; Chin, Hyung Min ; Yang, Seung Ho. / Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. In: Oncology Reports. 2015 ; Vol. 34, No. 4. pp. 2047-2053.
@article{b4e26ea5aa2844139b7536809733a5da,
title = "Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models",
abstract = "Gastric cancer is the second most common cause of cancer-related death worldwide. Although brain metastasis is a rare complication of gastric cancer, no standard therapy for gastric cancer brain metastasis has been established. We attempted to identify biological markers that predict brain metastasis, and investigated how to modulate such markers. A case-control study of patients newly diagnosed with gastric cancer who had developed brain metastasis during follow-up, was conducted. These patients were compared with patients who had advanced gastric cancer but no evidence of brain metastasis. Immunohistochemistry was used to analyze the expression of E-cadherin, N-cadherin, MSS1, claudin-3, claudin-4, Glut1, clusterin, ITGB4, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) and p53. The expression of VEGF tended to be higher in the case group (33.3 vs. 0{\%}, p=0.055). Median survival was significantly correlated with vascular invasion (12 vs. 33 months, p=0.008) and N-cadherin expression (36 vs. 12 months, p=0.027). We also investigated the effects of metformin in tumor-bearing mouse models. VEGF expression was decreased and E-cadherin increased in the metformin-treated group when compared with the control group. The expression of the mesenchymal marker MMP9 was decreased in the metformin-treated group. Brain metastasis of advanced gastric cancer was associated with the expression of VEGF. Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition.",
author = "Jun, {Kyong Hwa} and Lee, {Jung Eun} and Kim, {Se Hoon} and Jung, {Ji Han} and Choi, {Hyun Joo} and Kim, {Young Il} and Chin, {Hyung Min} and Yang, {Seung Ho}",
year = "2015",
month = "10",
day = "1",
doi = "10.3892/or.2015.4191",
language = "English",
volume = "34",
pages = "2047--2053",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. / Jun, Kyong Hwa; Lee, Jung Eun; Kim, Se Hoon; Jung, Ji Han; Choi, Hyun Joo; Kim, Young Il; Chin, Hyung Min; Yang, Seung Ho.

In: Oncology Reports, Vol. 34, No. 4, 01.10.2015, p. 2047-2053.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models

AU - Jun, Kyong Hwa

AU - Lee, Jung Eun

AU - Kim, Se Hoon

AU - Jung, Ji Han

AU - Choi, Hyun Joo

AU - Kim, Young Il

AU - Chin, Hyung Min

AU - Yang, Seung Ho

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Gastric cancer is the second most common cause of cancer-related death worldwide. Although brain metastasis is a rare complication of gastric cancer, no standard therapy for gastric cancer brain metastasis has been established. We attempted to identify biological markers that predict brain metastasis, and investigated how to modulate such markers. A case-control study of patients newly diagnosed with gastric cancer who had developed brain metastasis during follow-up, was conducted. These patients were compared with patients who had advanced gastric cancer but no evidence of brain metastasis. Immunohistochemistry was used to analyze the expression of E-cadherin, N-cadherin, MSS1, claudin-3, claudin-4, Glut1, clusterin, ITGB4, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) and p53. The expression of VEGF tended to be higher in the case group (33.3 vs. 0%, p=0.055). Median survival was significantly correlated with vascular invasion (12 vs. 33 months, p=0.008) and N-cadherin expression (36 vs. 12 months, p=0.027). We also investigated the effects of metformin in tumor-bearing mouse models. VEGF expression was decreased and E-cadherin increased in the metformin-treated group when compared with the control group. The expression of the mesenchymal marker MMP9 was decreased in the metformin-treated group. Brain metastasis of advanced gastric cancer was associated with the expression of VEGF. Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition.

AB - Gastric cancer is the second most common cause of cancer-related death worldwide. Although brain metastasis is a rare complication of gastric cancer, no standard therapy for gastric cancer brain metastasis has been established. We attempted to identify biological markers that predict brain metastasis, and investigated how to modulate such markers. A case-control study of patients newly diagnosed with gastric cancer who had developed brain metastasis during follow-up, was conducted. These patients were compared with patients who had advanced gastric cancer but no evidence of brain metastasis. Immunohistochemistry was used to analyze the expression of E-cadherin, N-cadherin, MSS1, claudin-3, claudin-4, Glut1, clusterin, ITGB4, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) and p53. The expression of VEGF tended to be higher in the case group (33.3 vs. 0%, p=0.055). Median survival was significantly correlated with vascular invasion (12 vs. 33 months, p=0.008) and N-cadherin expression (36 vs. 12 months, p=0.027). We also investigated the effects of metformin in tumor-bearing mouse models. VEGF expression was decreased and E-cadherin increased in the metformin-treated group when compared with the control group. The expression of the mesenchymal marker MMP9 was decreased in the metformin-treated group. Brain metastasis of advanced gastric cancer was associated with the expression of VEGF. Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition.

UR - http://www.scopus.com/inward/record.url?scp=84939148087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939148087&partnerID=8YFLogxK

U2 - 10.3892/or.2015.4191

DO - 10.3892/or.2015.4191

M3 - Article

C2 - 26260219

AN - SCOPUS:84939148087

VL - 34

SP - 2047

EP - 2053

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -